2017 Access DEA History 
WeedAdvisor
JUNE 1, 2019
The court, citing concerns over marijuana’s Schedule I status and its impact on medical users who need it most, essentially issued an ultimatum to the DEA. Like a child who does not want to clean his or her room, the DEA simply refuses to take any major action, despite the whirlwind of reforms surrounding them on a daily basis.
Cannabis Law Report
APRIL 8, 2022
To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. Lyle Craker, Ph.D., MAPS Founder Rick Doblin, Ph.D.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 1, 2021
In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency recognized psilocybin as a breakthrough therapy for treatment-resistant depression. Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries.
Cannabis Law Report
JUNE 15, 2021
Reinvests funds to support programs that work on expanding access to substance use treatment, support harm reduction services, and reduce the criminalization of individuals who use drugs by supporting the development or expansion of pre-arrest diversion programs. Ensures individuals with drug convictions can gain access to drivers’ licenses.
Cannabis Law Report
FEBRUARY 28, 2022
Patents on psychedelics raise unique concerns associated with their unusual qualities, history, and regulation. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. In 2017, the FDA designated MDMA a breakthrough therapy for PTSD. Johnson & Roland R.
Cannabis Law Report
JULY 9, 2021
Right to Try laws permit patients with serious or life-threatening diseases to access drugs that do not yet have government approval. Drug Enforcement Agency (“DEA”). Briefing is still under way, with the DEA’s responsive brief submitted on June 25, 2021, and the petitioners’ reply due July 16, 2021. AIMS Institute, PLLC.
Cannabis Law Report
SEPTEMBER 23, 2019
Cannabis use, both medically and recreationally, is prevalent throughout history. Surveying marijuana use is essential to gauge public health implications of increased access to marijuana, cannabinoid, and cannabis products. Background. Extensive evidence. 1 In the U.S. and 2.3%, respectively. and 2.3%, respectively.
Expert insights. Personalized for you.
55 
Let's personalize your content